Live Marvell Technology Vote →

Never Miss Important Company Updates Again

Get AI-powered summaries of SEC filings delivered to your inbox

Follow your favorite stocks and get email alerts when they release important updates. Completely free.

Covers 5,000+ public companies
Get started →
Sign up to stay up to date with the stocks you care about
Follow OnKure Therapeutics, Inc.

Get SEC filing alerts via email and in your feed for OnKure Therapeutics, Inc.

OKUR

OnKure Therapeutics, Inc.

About OnKure Therapeutics, Inc.

OnKure Therapeutics is a biopharmaceutical company specializing in precision cancer medicines. Its core focus is developing highly selective small molecule inhibitors targeting mutated oncogenes, particularly PI3Kα mutations in breast and other cancers. The company’s pipeline includes mutation-specific therapies designed to improve efficacy and safety, with a strategic emphasis on targeted, mutation-driven treatments for underserved patient populations in oncology.
This description was generated via AI from an annual report. Updated 8 months ago.

Latest SEC Filings from OnKure Therapeutics, Inc.

1
1
OnKure Therapeutics, Inc. OnKure Therapeutics Reports Q1 2026 Financial Results with $15.2M Net Loss

Via official filing (AI summary) | about 1 month ago | 0 comments

2
1
OnKure Therapeutics, Inc. OnKure Therapeutics Reports $59.5 Million Net Loss for 2025, Faces Funding Challenges

Via official filing (AI summary) | 3 months ago | 0 comments

3
1
OnKure Therapeutics, Inc. OnKure Therapeutics Reports $14.7 Million Net Loss in Q3 2025

Via official filing (AI summary) | 7 months ago | 0 comments

4
1
OnKure Therapeutics, Inc. OnKure Therapeutics Reports $31.3 Million Net Loss for First Half of 2025

Via official filing (AI summary) | 10 months ago | 0 comments

5
1
OnKure Therapeutics, Inc. OnKure Therapeutics Reports $15.9 Million Net Loss in Q1 2025, Sees Increased Operating Expenses

Via official filing (AI summary) | about 1 year ago | 0 comments

6
1
OnKure Therapeutics, Inc. OnKure Therapeutics Reports $52.7 Million Net Loss for 2024 Following Merger

Via official filing (AI summary) | about 1 year ago | 0 comments

7
1
OnKure Therapeutics, Inc. Reneo Pharmaceuticals Reports Financial Changes Following Merger with Legacy OnKure

Via official filing (AI summary) | over 1 year ago | 0 comments